Fletcher Mark A, Okasha Omar, Baay Marc, Syrochkina Maria, Hayford Kyla
Pfizer Vaccines Research & Development, Medical Affairs, Emerging Markets Region, 23-25 Avenue du Docteur Lannelongue, 75014, Paris, France.
P95 Clinical & Epidemiology Services, Diestsevest 125, 3000, Leuven, Belgium.
Eur J Clin Microbiol Infect Dis. 2025 May 2. doi: 10.1007/s10096-025-05114-8.
To estimate pneumococcal conjugate vaccine (PCV) national program impact on pneumococcal complicated pneumonia (PnCP) based on changes in PnCP population-based incidence, PnCP proportion of all-cause complicated pneumonia (or invasive pneumococcal disease), and PnCP serotype distribution.
MEDLINE, EMBASE, and Global Index Medicus articles (2001-March 2022) reporting laboratory-confirmed PnCP studies were stratified by age group, outcome measure, PCV program period(s) (pre-PCV, transition, and post-PCV), serotype distribution (based on serotyping methodology used), and PCV serotype formulation. Random effect meta-analysis of the total number of serotyped isolates within each study was used to calculate pooled serotype-specific percentages.
Of 1360 publications screened, the 134 studies included from 30 countries differed widely by methodological approaches. Pediatric PnCP incidence tended to decline from pre-PCV to post-PCV periods, as did PnCP as a proportion of all-cause complicated pneumonia from transition to post-PCV periods. Studies describing changes in serotype distribution by PCV program period applied detection methods that varied from pre-PCV period microbiological culture with Quellung serotyping to in the transition and post-PCV periods molecular methods like PCR. Meta-analysis revealed near elimination of pediatric PCV7-serotype PnCP between pre- and post-PCV, while the PCV13nonPCV7 percentage increased from 51.1% pre-PCV period to 76.5% in the transition period, remaining stable post-PCV period. Non-PCV13 serotypes increased slightly from low baseline numbers. Adult data were lacking or inconsistent.
Although studies were heterogeneous, pediatric PnCP incidence and proportion tended to decline from pre-PCV to post-PCV periods, and PCV13nonPCV7 serotype distribution percentage remained unchanged from transition to post-PCV period. Standardization of PnCP surveillance methods, definitions, and reporting is needed to evaluate accurately PCV program impact.
基于肺炎球菌复杂性肺炎(PnCP)人群发病率、PnCP在所有病因所致复杂性肺炎(或侵袭性肺炎球菌病)中的比例以及PnCP血清型分布的变化,评估肺炎球菌结合疫苗(PCV)国家计划对PnCP的影响。
检索MEDLINE、EMBASE和全球医学索引(2001年至2022年3月)中报告实验室确诊的PnCP研究,按年龄组、结局指标、PCV计划实施阶段(PCV前、过渡阶段和PCV后)、血清型分布(基于所使用的血清分型方法)以及PCV血清型配方进行分层。对每项研究中血清分型分离株的总数进行随机效应荟萃分析,以计算合并的血清型特异性百分比。
在筛选的1360篇出版物中,来自30个国家的134项研究在方法学上差异很大。儿童PnCP发病率从PCV前到PCV后时期呈下降趋势,PnCP在所有病因所致复杂性肺炎中的比例从过渡阶段到PCV后时期也呈下降趋势。描述不同PCV计划阶段血清型分布变化的研究应用的检测方法各不相同,从PCV前时期的微生物培养及荚膜肿胀试验血清分型到过渡阶段和PCV后时期的PCR等分子方法。荟萃分析显示,PCV前到PCV后时期儿童PCV7血清型PnCP几乎消除,而PCV13非PCV7血清型的百分比从PCV前时期的51.1%增加到过渡阶段的76.5%,在PCV后时期保持稳定。非PCV13血清型从低基线数量略有增加。缺乏成人数据或数据不一致。
尽管研究存在异质性,但儿童PnCP发病率和比例从PCV前到PCV后时期呈下降趋势,且PCV13非PCV7血清型分布百分比从过渡阶段到PCV后时期保持不变。需要对PnCP监测方法、定义和报告进行标准化,以准确评估PCV计划的影响。